| BUY ALERT Dear Leah, Healthcare has entered the "Age of AI," and no major drug company wants to be left behind. But betting on a hit-or-miss biotech company may not be the best way to capitalize. Instead, at this early stage of the opportunity, select big-cap drug companies may offer better risk-reward profiles. I'm recommending three such companies today. Hit the button below for more details. Click Here to Learn More Regards, |
 |
| Eric Fry
Editor, Fry's Investment Report |
Tidak ada komentar:
Posting Komentar